Market Closed -
London S.E.
11:35:29 2024-04-30 EDT
|
5-day change
|
1st Jan Change
|
232
GBX
|
+2.65%
|
|
+6.91%
|
+36.47%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
90.09
|
105.1
|
120.1
|
207.3
|
136.7
|
135.8
|
135.8
|
-
|
Enterprise Value (EV)
1 |
113.7
|
122.9
|
133.7
|
212.6
|
142.1
|
102.2
|
108.7
|
104.7
|
P/E ratio
|
-88.2
x
|
-79.5
x
|
500
x
|
-3,450
x
|
-
|
-
|
-
|
-
|
Yield
|
2.93%
|
1.14%
|
2%
|
1.28%
|
1.93%
|
1.95%
|
2.21%
|
2.21%
|
Capitalization / Revenue
|
1.24
x
|
1.48
x
|
1.7
x
|
2.8
x
|
1.91
x
|
1.37
x
|
1.81
x
|
1.74
x
|
EV / Revenue
|
1.57
x
|
1.73
x
|
1.9
x
|
2.87
x
|
1.98
x
|
1.37
x
|
1.45
x
|
1.35
x
|
EV / EBITDA
|
9.64
x
|
9.36
x
|
11.1
x
|
15.8
x
|
10.8
x
|
7.67
x
|
9.37
x
|
8.24
x
|
EV / FCF
|
-
|
-
|
15.4
x
|
19.7
x
|
21.4
x
|
17.3
x
|
3.47
x
|
10.4
x
|
FCF Yield
|
-
|
-
|
6.49%
|
5.08%
|
4.67%
|
5.76%
|
28.8%
|
9.64%
|
Price to Book
|
-
|
1.28
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
60,057
|
60,057
|
60,057
|
60,092
|
60,092
|
60,108
|
60,108
|
-
|
Reference price
2 |
1.500
|
1.750
|
2.000
|
3.450
|
2.275
|
2.260
|
2.260
|
2.260
|
Announcement Date
|
19-04-30
|
20-05-28
|
21-03-30
|
22-03-29
|
23-03-28
|
24-04-09
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
72.47
|
71.12
|
70.49
|
74.02
|
71.62
|
74.35
|
74.85
|
77.85
|
EBITDA
1 |
11.8
|
13.14
|
12.09
|
13.46
|
13.13
|
13.33
|
11.6
|
12.72
|
EBIT
1 |
9.604
|
9.462
|
8.561
|
10.59
|
9.753
|
9.807
|
9.1
|
10.7
|
Operating Margin
|
13.25%
|
13.3%
|
12.14%
|
14.31%
|
13.62%
|
13.19%
|
12.16%
|
13.74%
|
Earnings before Tax (EBT)
|
-
|
-1.608
|
0.199
|
0.945
|
-
|
-
|
-
|
-
|
Net income
1 |
-
|
-1.338
|
0.234
|
-0.077
|
1.965
|
1.199
|
28.4
|
5.4
|
Net margin
|
-
|
-1.88%
|
0.33%
|
-0.1%
|
2.74%
|
1.61%
|
37.94%
|
6.94%
|
EPS
|
-0.0170
|
-0.0220
|
0.004000
|
-0.001000
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
8.682
|
10.81
|
6.635
|
7.9
|
31.3
|
10.1
|
FCF margin
|
-
|
-
|
12.32%
|
14.6%
|
9.26%
|
10.62%
|
41.82%
|
12.97%
|
FCF Conversion (EBITDA)
|
-
|
-
|
71.81%
|
80.33%
|
50.53%
|
60.08%
|
269.83%
|
79.43%
|
FCF Conversion (Net income)
|
-
|
-
|
3,710.26%
|
-
|
337.66%
|
183.72%
|
110.21%
|
187.04%
|
Dividend per Share
2 |
0.0440
|
0.0200
|
0.0400
|
0.0440
|
0.0440
|
0.0440
|
0.0500
|
0.0500
|
Announcement Date
|
19-04-30
|
20-05-28
|
21-03-30
|
22-03-29
|
23-03-28
|
24-04-09
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
23.6
|
17.8
|
13.6
|
5.33
|
5.4
|
1.2
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
27.1
|
31.1
|
Leverage (Debt/EBITDA)
|
1.999
x
|
1.356
x
|
1.126
x
|
0.3961
x
|
0.4114
x
|
0.0913
x
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
8.68
|
10.8
|
6.64
|
7.9
|
31.3
|
10.1
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
1.360
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
0.1200
|
0.2200
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.21
|
-
|
2.44
|
3.22
|
2.79
|
4.2
|
4
|
3
|
Capex / Sales
|
0.29%
|
-
|
3.45%
|
4.34%
|
3.9%
|
5.65%
|
5.34%
|
3.85%
|
Announcement Date
|
19-04-30
|
20-05-28
|
21-03-30
|
22-03-29
|
23-03-28
|
24-04-09
|
-
|
-
|
Last Close Price
2.26
GBP Average target price
2.935
GBP Spread / Average Target +29.87% Consensus |
1st Jan change
|
Capi.
|
---|
| +36.47% | 170M | | -18.98% | 72.97B | | -11.71% | 6.69B | | -3.48% | 3.13B | | +2.36% | 1.44B | | -15.13% | 1.34B | | -7.91% | 1.25B | | -25.63% | 1.24B | | -10.84% | 1.15B | | 0.00% | 1.01B |
Veterinary Drugs
|